Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2026)

Amylyx Pharmaceuticals has reported Total Current Liabilities for 6 years, with the latest figure at $21.2 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 1.28% year-over-year to $21.2 million in Q2 2026; TTM through Jun 2026 was $21.2 million, a 1.28% decrease from a year earlier, with the FY2025 full-year figure at $22.7 million, down 20.13% from the prior year.
• Total Current Liabilities was $21.2 million for Q2 2026 at Amylyx Pharmaceuticals, up from $16.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $91.6 million in Q1 2024, with the low at $16.0 million in Q1 2026.
• Average Total Current Liabilities over 5 years is $41.5 million, with a median of $30.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 167.93% in 2022, then tumbled 80.43% in 2025.
• Over 5 years, Total Current Liabilities stood at $46.6 million in 2022, then soared by 76.02% to $82.0 million in 2023, then plunged by 65.38% to $28.4 million in 2024, then fell by 20.13% to $22.7 million in 2025, then dropped by 6.78% to $21.2 million in 2026.
• The last three Total Current Liabilities figures came in at $21.2 million (Q2 2026), $16.0 million (Q1 2026), and $22.7 million (Q4 2025), per Business Quant data.